Results 141 to 150 of about 27,075 (224)

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

MedComm – Oncology, Volume 5, Issue 3, September 2026.
The up‐to‐date clinical progress of immune checkpoint inhibitor (ICI) therapy in solid tumors, specifically the combinational regimens between ICIs and other treatment strategies, the mechanisms underlying primary and acquired resistance, and mechanism‐matched strategies to improve clinical outcomes are synthesized in this review.
Qiongyu Zhang, Zhi Qin, Caijuan Guo
wiley   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, Volume 15, Issue 3, Page 164-175, September 2026.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Radiotherapy and Immunotherapy In Hepatocellular Carcinoma: Priming the Tumor Immune Microenvironment From Bench To Bedside

Precision Radiation Oncology, Volume 10, Issue 3, Page 417-427, September 2026.
The dual immunomodulatory network of radiotherapy in hepatocellular carcinoma. Radiotherapy initiates its effects by inducing immunogenic cell death and DNA double‐strand breaks. Immune Activation: Cytosolic DNA from damaged cells activates the cGAS‐STING pathway, triggering IRF3/NF‐κB‐mediated type I interferon production. This enhances dendritic cell
Zhigang Fu, Yang Zhang, Zuomin Wang, Zongjuan Li, Shisuo Du   +4 more
wiley   +1 more source

Combination of PARP inhibitor olaparib and a vascular disrupting agent reduces tumor growth in a preclinical model of prostate cancer. [PDF]

Cancer Chemother Pharmacol
Sereti E, Evans-Axelsson S, Törnell J, Rehnmark S, Högberg M, Bjartell A.   +5 more
europepmc   +1 more source

Pharmacokinetic boosting of olaparib to improve exposure, tolerance and cost-effectiveness part A

Item does not contain fulltextBackground: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure.
Mohmaed Ali, M.I., Koolen, S.L.W., Overbeek, J.K., Heine, R. ter, Ottevanger, P.B., Bloemendal, H.J., Erp, N. van, Guchelaar, N.A.D.   +7 more
core   +1 more source

Breaking Physiological Barriers in Women's Health: Mucoadhesive and Stimuli‐Responsive Nanomaterials

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 5, September/October 2026.
Drug delivery vehicles generated from biomaterials for women's health. In particular, the breast and the reproductive system, including the ovary, uterus, cervix, vagina, and the surrounding tissues, targeted drug delivery. BioRender. ABSTRACT Biomaterials are natural or synthetic molecules that exhibit biocompatibility, biodegradability, or ...
Maddox Parsons, Alivia R. Parker, Luke Schneider, Trisha Sullivan, Brittany E. Givens   +4 more
wiley   +1 more source

Focal adhesion kinase inhibitor defactinib enhances olaparib-induced suppression of BRCA-proficient breast cancer cell proliferation. [PDF]

Oncol Lett
Ono H, Taniguchi K, Yasuda S, Sukeno M, Matsui T, Naoi Y, Horinaka M, Sakai T.   +7 more
europepmc   +1 more source

Factors influencing oncologists' decisions for germline BRCA testing and adjuvant therapy selection in HER2-negative early breast cancer. [PDF]

Front Oncol
Li Q, Cambron-Mellott MJ, Xu X, Kashine-Tack N, Hayes JF, Mishkin KE, Gordon A, Will O, Howell LA, Noval A, Beusterien K.   +10 more
europepmc   +1 more source